|
Mutation Information
|
Mutation Site
|
T66I |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
IN |
|
Relevant Drug
|
dolutegravir (DTG) |
Literature Information
|
PubMed PMID
|
27539455
|
|
Published Year
|
2016 |
|
Journal
|
Infectious diseases and therapy |
|
Title
|
New Antiretroviral Treatment for HIV. |
|
Author
|
Badowski ME,Pérez SE,Biagi M,Littler JA |
|
Evidence
|
Although the risk is low, a retrospective analysis performed in British Columbia documented three cases of dolutegravir resistance (two ART-experienced patients developed R263 K and one ART-naive patient developed T66I). Dolutegravir/lamivudine/abacavir is co-formulated as a STR given once daily and has been associated with an increased serum creatinine (SCr) secondary to inhibiting tubular secretion of creatinine, but glomerular function was unaffected.
|
|
|
HIV Mutation Detail Information